That's quite a handsome return. Which BMS feels empowered to do to since they can charge exorbitant amounts for it

I often am against the narrative that every pill should be priced at the cost of manufacturing + healthy margin, since by that logic the first pill should cost billions to cover for the R&D. In this case, it doesn't quite translate.